Transition partner enrols first patient in AD study
Transition Therapeutics’ (TSX:TTH; NASDAQ:TTHI) licensing partner, Elan Corp., has enrolled the first patient in a Phase 2 study of ELND005 for the treatment of agitation/aggression in patients with...
View ArticleTransition, Perrigo amend ELND005 program
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) and Perrigo plc (NYSE,TASE:PRGO) have amended the development and commercialization program for their ELND005 drug candidate, which is being investigated...
View Article
More Pages to Explore .....